Pulmonary Arterial Hypertension in a Patient with β‐Thalassemia Intermedia and Reversal with Infusion Epoprostenol Then Transition to Oral Calcium Channel Blocker Therapy: Review of Literature
Open Access
- 1 September 2014
- journal article
- review article
- Published by Wiley in Pulmonary Circulation
- Vol. 4 (3) , 520-526
Abstract
Pulmonary arterial hypertension (PAH) is a potentially life‐threatening complication of thalassemia. A sexagenarian with β‐thalassemia intermedia presented with new‐onset dyspnea and syncope. Right heart catheterization confirmed severe PAH. Her functional class IV symptoms and severely elevated mean pulmonary artery pressure prompted the initiation of continuous epoprostenol therapy. Clinical follow‐up documented significant improvement in functional class, 6‐minute walk distance, and right ventricular size and function as well as pulmonary arterial pressure on echocardiogram. At the patient's request, epoprostenol was down‐titrated and eventually discontinued. The patient was then safely transitioned to nifedipine therapy after verification of vasoresponsiveness.Keywords
This publication has 26 references indexed in Scilit:
- Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertensionHaematologica, 2013
- Successful Epoprostenol Withdrawal in Pulmonary Arterial Hypertension: Case Report and Literature ReviewRespiratory Care, 2012
- Pulmonary hypertension in thalassemiaAnnals of the New York Academy of Sciences, 2010
- PULMONARY HYPERTENSION IN β-THALASSEMIA MAJOR AND THE ROLE OF L-CARNITINE THERAPYPediatric Hematology and Oncology, 2008
- Pulmonary hypertension and β-thalassemia major: Report of a case, its treatment, and a review of the literatureAmerican Journal of Hematology, 2006
- Pulmonary hypertension in thalassaemia major patients with normal left ventricular systolic functionBritish Journal of Haematology, 2006
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Survival in Primary Pulmonary HypertensionCirculation, 2002
- Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertensionHeart, 2000
- The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary HypertensionNew England Journal of Medicine, 1992